Page 193 - Fluorescence-guided cancer surgery

REFERENCES
12. Snoeks TJ, van Driel PB, Keereweer S et al. Towards a successful clinical implementation of uorescence-guided surgery. Mol Imaging Biol 2014;16:147-151.
1. Kelderhouse LE, Chelvam V, Wayua C et
al. Development of tumor-targeted near infrared probes for uorescence guided 13. surgery. Bioconjug Chem 2013;24:1075-1080.
Cohen A. Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies. Clin Pharmacokinet 2008;47:373-381.
Danhof M, Alvan G, Dahl SG, Kuhlmann
2. Altintas I, Kok RJ, Schi elers RM. Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies 14. to nanobodies. Eur J Pharm Sci 2012;45:399-
J, Paintaud G. Mechanism-based 407. pharmacokinetic-pharmacodynamic
3. Choi HS, Gibbs SL, Lee JH et al. Targeted zwitterionic near-infrared uorophores for improved optical imaging. Nat Biotechnol 15. 2013;31:148-153.
4. Oliveira S, Heukers R, Sornkom J, Kok RJ,
van Bergen En Henegouwen PM. Targeting tumors with nanobodies for cancer imaging 16. and therapy. J Control Release 2013;172:607-
modeling-a new classi cation of biomarkers. Pharm Res 2005;22:1432-1437.
Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 2012;503:255-268.
Kapiteijn E, Marijnen CA, Nagtegaal ID et al.
Preoperative radiotherapy combined with 617. total mesorectal excision for resectable
5. Rosenthal EL, Warram JM, de BE et al.
Safety and Tumor Speci city of Cetuximab- 17.
IRDye800 for Surgical Navigation in Head and
Neck Cancer. Clin Cancer Res 2015;21:3658-
3666. Syst Rev 2007;CD005002.
6. Zinn KR, Korb M, Samuel S et al. IND- 18. directed safety and biodistribution study of intravenously injected cetuximab-IRDye800
in cynomolgus macaques. Mol Imaging Biol 2015;17:49-57.
7. Chi C, Du Y, Ye J et al. Intraoperative imaging- 19. guided cancer surgery: from current uorescence molecular imaging methods to future multi-modality imaging technology. Theranostics 2014;4:1072-1084.
8. Bai J, Wang JT, Rubio N et al. Triple- 20. Modal Imaging of Magnetically-Targeted Nanocapsules in Solid Tumours In Vivo. Theranostics 2016;6:342-356.
9. Zhu B, Sevick-Muraca EM. A review of 21. performance of near-infrared uorescence imaging devices used in clinical studies. Br J
Radiol 2015;88:20140547.
10. Pleijhuis R, Timmermans A, De JJ, de BE, Ntziachristos V, Van DG. Tissue-simulating phantoms for assessing potential near- infrared uorescence imaging applications in breast cancer surgery. J Vis Exp 2014;51776.
11. Rosenthal EL, Warram JM, de BE et al. Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report. J Nucl Med 2016;57:144- 150.
Glynne-Jones R, Wallace M, Livingstone JI, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a “wait and see” policy justi ed? Dis Colon Rectum 2008;51:10-19.
Jin HL, Zhu H, Ling TS, Zhang HJ, Shi RH. Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta- analysis. World J Gastroenterol 2009;15:5983- 5991.
O’Neill BD, Brown G, Heald RJ, Cunningham D, Tait DM. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol 2007;8:625-633.
Pozo ME, Fang SH. Watch and wait approach to rectal cancer: A review. World J Gastrointest Surg 2015;7:306-312.
Summary and future perspectives 191
rectal cancer. N Engl J Med 2001;345:638-646.
Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database
22. Beets GL, Figueiredo NL, Habr-Gama A, van de Velde CJ. A new paradigm for rectal cancer: Organ preservation: Introducing the International Watch & Wait Database (IWWD). Eur J Surg Oncol 2015;41:1562-1564.